kabutan

Veritas In Silico Inc.(130A) Summary

130A
TSE Growth
Veritas In Silico Inc.
467
JPY
+3
(+0.65%)
Mar 13, 3:30 pm JST
2.92
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.70
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
456 JPY 2.86 USD
Previous Close Mar 12
464 JPY 2.91 USD
High Mar 13, 3:14 pm
468 JPY 2.93 USD
Low Mar 13, 9:00 am
456 JPY 2.86 USD
Volume
17,400
Trading Value
8.00M JPY 0.05M USD
VWAP
463.04 JPY 2.91 USD
Minimum Trading Value
46,700 JPY 292 USD
Market Cap
3.03B JPY 0.02B USD
Number of Trades
90
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
420
1-Year High Jul 31, 2025
10,270
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 376,900
Feb 27, 2026 0 401,800
Feb 20, 2026 0 418,100
Feb 13, 2026 0 431,400
Feb 6, 2026 0 446,800
Company Profile
Veritas In Silico operates a platform business for small molecule and nucleic acid drug discovery targeting mRNA.
Sector
Pharmaceuticals
Veritas In Silico Inc. is a Japan-based bio-pharmaceutical company. The company develops a platform for small molecule and nucleic acid drug discovery, specializing in targeting mRNA. It focuses on diseases that cannot be addressed by conventional protein-targeted drug discovery approaches. Using their proprietary in silico RNA structure analysis technology, Veritas In Silico has realized a drug discovery approach that targets partial structures on mRNA. This enables the creation of pharmaceuticals that address unmet medical needs. The company collaborates with multiple pharmaceutical companies, promoting joint research based on their drug discovery platform "ibVIS". By targeting mRNA, Veritas In Silico aims to open up new possibilities in the field of drug discovery and development.